Evidence map›Paper›PMID 39016058›Full record

ArticleImmunotherapy2024

Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.

Beliz Bahar Karaoğlan, Emre Yekedüz, Satı Coşkun Yazgan, Eda Eylemer Mocan, Elif Berna Köksoy, Hatime Arzu Yaşar, Filiz Çay Şenler, Güngör Utkan, Ahmet Demirkazık, Hakan Akbulut and 1 more

Abstract read
In one paragraph

Article in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Beliz Bahar KaraoğlanAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.ORCID 0000-0002-5021-7588
Emre YekedüzDana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02215, USA.ORCID 0000-0001-6819-5930
Satı Coşkun YazganAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.ORCID 0000-0002-2979-9974
Eda Eylemer MocanAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.ORCID 0000-0003-0429-8142
Elif Berna KöksoyAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.ORCID 0000-0002-6590-4444
Hatime Arzu YaşarAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.ORCID 0000-0002-0545-1383
Filiz Çay ŞenlerAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.ORCID 0000-0002-7156-4650
Güngör UtkanAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.ORCID 0000-0001-8445-6993
Ahmet DemirkazıkAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.ORCID 0000-0002-2917-7999
Hakan AkbulutAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.ORCID 0009-0009-0015-2630
Yüksel ÜrünAnkara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.ORCID 0000-0002-9152-9887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immune Checkpoint InhibitorsNeoplasmsSodiumAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsSurvival AnalysisImmune Checkpoint InhibitorsSodiumcancerhyponatremiaimmune checkpoint inhibitorimmunotherapytumor

Identifiers

PMID39016058
PMCPMC11457628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.